Overview Request Sample Pages Request Customization Download PDF
You are viewing: UAE Preimplantation Genetic Testing Market analysis

The UAE Preimplantation Genetic Testing Market was valued at $1.6 Million in 2025 and projected to reach to $2.6 Million by 2030, representing a compound annual growth rate of 9.9%. The UAE preimplantation genetic testing market is poised for sustained growth through 2030, supported by increasing adoption of assisted reproductive technologies and growing awareness among UAE residents seeking advanced fertility solutions.

UAE Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UAE Preimplantation Genetic Testing Market Trends and Insights

  • Valued at USD 1.6 million in 2025, the UAE market is projected to expand to USD 2.6 million by 2030, reflecting a compound annual growth rate of 9.9%.
  • This growth trajectory in the UAE is underpinned by increasing adoption of assisted reproductive technologies, rising awareness of genetic screening benefits, and strengthening healthcare infrastructure across the emirate. The UAE's market expansion is driven by several converging factors specific to the region's healthcare ecosystem.
  • The UAE has witnessed substantial investment in fertility clinics and diagnostic centers, with growing patient demand for advanced genetic testing services.
  • By 2030, the UAE is expected to capture an increasingly significant share of regional PGT demand, supported by favorable regulatory frameworks and high healthcare spending.
  • The UAE's position as a regional medical hub continues to attract both domestic and cross-border patients seeking cutting-edge reproductive genetic services. Market dynamics in the UAE reflect broader trends in personalized medicine and preventive healthcare.
  • The UAE's emphasis on precision medicine adoption and government support for advanced diagnostics are expected to sustain momentum through 2030.
  • As the UAE healthcare sector matures, preimplantation genetic testing is becoming an integral component of fertility treatment protocols, positioning the market for sustained double-digit growth..

Key Market Statistics

  • CAGR (2025-2030) 9.9% CAGR
  • Market Size, 2025 ~USD 1.6 Million
  • Forecast, 2030 ~USD 2.6 Million
  • Country UAE

UAE Preimplantation Genetic Testing Market Overview

Market Valuation :

The UAE preimplantation genetic testing market is valued at USD 1.6 million in 2025, with strong growth momentum driven by increasing healthcare investments and fertility awareness across the Emirates.

Robust CAGR Growth :

The UAE market is expanding at a 9.9% CAGR from 2025 to 2030, slightly below the global average of 10.5%, reflecting steady adoption of advanced reproductive technologies in the region.

GCC Leadership Position :

As a high-growth segment within the GCC region's reproductive healthcare landscape, the UAE is establishing itself as a regional hub for assisted reproductive technology and genetic testing services.

Forecast Expansion :

The market is projected to reach USD 2.6 million by 2030, representing a 62.5% increase over the five-year forecast period, driven by rising disposable incomes and healthcare accessibility.

UAE Preimplantation Genetic Testing Market Dynamics

  • Government healthcare initiatives, coupled with the presence of world-class medical facilities in Dubai and Abu Dhabi, are accelerating market penetration and patient accessibility to PGT services. Rising disposable incomes, changing family planning preferences, and the region's position as a medical tourism destination are key catalysts for market expansion.
  • Enhanced regulatory frameworks and investment in reproductive healthcare infrastructure will further strengthen the UAE's market position within the GCC, attracting both local and international fertility centers to expand their PGT offerings..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • The UAE preimplantation genetic testing market is valued at USD 1.6 million in 2025 and is forecast to reach USD 2.6 million by 2030.
      • The UAE market is growing at a 9.9% CAGR, driven by increased adoption of assisted reproductive technologies and genetic screening awareness.
      • The UAE's position as a regional medical hub and investment in fertility infrastructure are key growth catalysts through 2030.
      • The UAE's regulatory support and high healthcare spending underpin sustained market expansion in preimplantation genetic testing services.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      UAE Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES0.440.470.510.560.610.670.750.8310.3
      FERTILITY CLINICS1.241.321.421.551.691.862.052.269.7
      HOSPITALS0.310.330.350.380.410.450.490.548.6
      OTHER END USERS0.110.110.120.130.140.150.160.177.7
      TOTAL2.092.232.412.622.863.133.443.89.6

      Target Audience

      • Fertility Clinic Operators : UAE-based and international fertility centers need market data to assess expansion opportunities, benchmark service offerings, and understand local demand for PGT services across the Emirates.
      • Medical Device & Diagnostics Companies : Manufacturers of genetic testing equipment and diagnostic solutions require UAE-specific market insights to develop localized go-to-market strategies and identify distribution partnerships.
      • Healthcare Investors & PE Firms : Investment professionals evaluating reproductive healthcare opportunities in the GCC need detailed UAE market analysis to assess valuations, growth potential, and investment returns.
      • Government & Healthcare Policymakers : UAE health authorities and regulatory bodies use market intelligence to inform healthcare policy, infrastructure planning, and guidelines for reproductive medicine and genetic testing services.
      • Pharmaceutical & Biotech Companies : Organizations developing fertility treatments and genetic screening solutions need UAE market data to prioritize regional commercialization efforts and identify clinical partnership opportunities.

      Key Companies in the UAE Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • UAE-Specific Market Sizing : Obtain precise market valuation data for the UAE PGT segment (USD 1.6M in 2025), enabling accurate financial forecasting and investment decisions tailored to the Emirates market.
      • Regional Competitive Intelligence : Understand the UAE's position within the GCC reproductive healthcare landscape and identify competitive opportunities specific to Dubai, Abu Dhabi, and other emirates.
      • Growth Trajectory Insights : Access detailed 5-year forecast data (9.9% CAGR through 2030) to benchmark performance expectations and plan market entry or expansion strategies in the UAE fertility sector.
      • Localized Adoption Drivers : Gain insights into UAE-specific factors driving PGT adoption, including healthcare infrastructure development, regulatory environment, and patient demographics in the region.
      • Strategic Investment Planning : Leverage UAE market intelligence to identify high-potential segments, partnership opportunities, and expansion pathways within the growing assisted reproductive technology ecosystem.

      Frequently asked questions

      What is the current market size of preimplantation genetic testing in the UAE?

      The UAE preimplantation genetic testing market is valued at USD 1.6 million in 2025, based on verified market data.

      What is the projected market size for the UAE by 2030?

      The UAE preimplantation genetic testing market is forecast to reach USD 2.6 million by 2030, representing significant growth from 2025 levels.

      What is the growth rate of the UAE preimplantation genetic testing market?

      The UAE market is expanding at a compound annual growth rate of 9.9% between 2025 and 2030.

      What factors are driving growth in the UAE preimplantation genetic testing market?

      Key drivers in the UAE include increased adoption of assisted reproductive technologies, rising awareness of genetic screening benefits, investment in fertility infrastructure, and supportive regulatory frameworks.

      How does the UAE market compare to other GCC countries?

      The UAE represents a significant segment within the GCC preimplantation genetic testing market, with strong growth momentum supported by its position as a regional medical hub and advanced healthcare infrastructure.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status